The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of DZD8586, a non-covalent BBB penetrant LYN/BTK dual inhibitor, as monotherapy in relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL; TAI-SHAN9).
 
Luigui Qiu
No Relationships to Disclose
 
Yajun Li
No Relationships to Disclose
 
Keshu Zhou
No Relationships to Disclose
 
Ming Jiang
No Relationships to Disclose
 
Wei Liu
No Relationships to Disclose
 
Zhiming Li
No Relationships to Disclose
 
Meifang Zheng
No Relationships to Disclose
 
Zengjun Li
No Relationships to Disclose
 
Wenbin Qian
No Relationships to Disclose
 
Mei Lan
No Relationships to Disclose
 
Pengcheng He
No Relationships to Disclose
 
Kaiyang Ding
No Relationships to Disclose
 
Fang Zhu
No Relationships to Disclose
 
Hongmei Jing
No Relationships to Disclose
 
Ziyi Liu
Employment - Dizal Pharma
Stock and Other Ownership Interests - Dizal Pharma
 
Lihua Qiu
No Relationships to Disclose